← Back to Search

CAR T-cell Therapy

MT-601 for Lymphoma (APOLLO Trial)

Phase 1
Recruiting
Research Sponsored by Marker Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up after 3 or 6 patients in each dose cohort have been treated with mt-601 and have had the opportunity to be followed for 28 days.
Awards & highlights

APOLLO Trial Summary

This trial is testing a new drug for relapsed/refractory non-Hodgkin lymphoma. It'll measure safety and effectiveness of the drug.

Who is the study for?
This trial is for adults over 18 with relapsed or refractory Non-Hodgkin Lymphoma who have a life expectancy of at least 12 weeks and are in relatively good health (Karnofsky/Lansky score ≥70). They must have their own cells available to create MT-601, meet blood, liver, and kidney function requirements, agree to birth control measures, and not be pregnant or breastfeeding. Those ineligible for CD19+ CAR T cell therapy may also join.Check my eligibility
What is being tested?
The study tests the safety and effectiveness of MT-601 on patients with Non-Hodgkin Lymphoma that has returned or resisted treatment. It's a Phase 1 trial involving multiple centers where participants receive a flat dose of MT-601 made from their own cells to see how well it works against their lymphoma.See study design
What are the potential side effects?
While specific side effects are not listed here, similar therapies often include risks such as immune reactions, infusion-related symptoms like fever or chills, fatigue, blood abnormalities, infections due to weakened immunity, organ inflammation and potential complications related to underlying health conditions.

APOLLO Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~after 3 or 6 patients in each dose cohort have been treated with mt-601 and have had the opportunity to be followed for 28 days.
This trial's timeline: 3 weeks for screening, Varies for treatment, and after 3 or 6 patients in each dose cohort have been treated with mt-601 and have had the opportunity to be followed for 28 days. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Dose Escalation
Dose Expansion (CR)
Dose Expansion (DOR)
+1 more

APOLLO Trial Design

1Treatment groups
Experimental Treatment
Group I: Single Arm StudyExperimental Treatment1 Intervention
Single arm study evaluating MT-601 investigational product at 200 million cells and 400 million cells per dose

Find a Location

Who is running the clinical trial?

Marker Therapeutics, Inc.Lead Sponsor
5 Previous Clinical Trials
431 Total Patients Enrolled

Media Library

MT-601 (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05798897 — Phase 1
Non-Hodgkin's Lymphoma Research Study Groups: Single Arm Study
Non-Hodgkin's Lymphoma Clinical Trial 2023: MT-601 Highlights & Side Effects. Trial Name: NCT05798897 — Phase 1
MT-601 (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05798897 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Will individuals aged 25 and above be accepted into the investigation?

"This medical study is seeking out individuals aged 18 and above, not exceeding the century mark."

Answered by AI

Has the Single Arm Study been sanctioned by the FDA?

"Due to the limited data available on Single Arm Study, our team at Power gave it a safety rating of 1. This is because this is only a Phase 1 trial and there is minimal evidence confirming its efficacy or safety."

Answered by AI

Is participation in this clinical trial open to me?

"Applicants must have been diagnosed with non-Hodgkin's lymphoma and be aged between 18 - 100 to take part in this clinical trial. In total, 37 participants are being considered for enrollment."

Answered by AI

What is the capacity for participants in this clinical trial?

"In order to facilitate this clinical trial, 37 individuals that meet the requirements must be identified. Marker Therapeutics Inc., will administrating the research from two different locations – Colorado Blood Cancer Institute (Sarah Cannon) in Denver and Tennessee Oncology PLLC in Nashville."

Answered by AI

Are applications currently being accepted for this investigation?

"Affirmative. Clinicaltrials.gov has verified that recruitment is still open for this medical trial, which was first announced on February 1st 2023 and most recently updated on April 4th 2023. The study is looking to enrol 37 patients from a total of four sites."

Answered by AI

In what locations are the experiments associated with this study being conducted?

"The medical study is enlisting volunteers from 4 different operating sites, such as Colorado Blood Cancer Institute (Sarah Cannon) in Denver and Tennessee Oncology PLLC in Nashville; with additional research facilities located at Sarah Cannon Research Institute at St. David's South Austin in Austin and other locales."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
2023. "Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05798897.
~25 spots leftby Feb 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top